AstraZeneca’s fixed-dose triple-combination therapy BREZTRI Aerosphere® (budesonide/glycopyrrolate/formoterol fumarate or BGF 320/36/9.6μg) has been approved in ...
WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results